Last updated: February 4, 2026
What is the case about?
GERON CORPORATION filed a patent infringement lawsuit against KAPPOS, the then Commissioner of the United States Patent and Trademark Office (USPTO), arising from the USPTO's rejection or invalidation of GERON's patent claims. The core issue involves the patent office’s procedures, interpretations of patent law, and GERON’s claims of improper patent rejection.
What are the key legal questions?
The case revolves around:
- The validity of GERON's patent claims for specific biotechnology inventions.
- The procedural correctness of the USPTO's reexamination or rejection procedures.
- Whether the USPTO, under Kappos's leadership, applied the law correctly, especially concerning obviousness and patent-eligibility criteria.
How was the case litigated?
GERON challenged USPTO decisions through a civil rights or administrative review process, filing in the District Court for the District of Columbia. The defendant, Kappos, was sued in his official capacity, defending the USPTO's actions under statutory and regulatory frameworks.
What are the notable procedural points?
- The initial patent application by GERON was rejected based on prior art references.
- GERON initiated administrative appeals, which were denied.
- The company then filed suit, alleging that the USPTO's rejection was arbitrary and contrary to patent law.
- Kappos, representing the USPTO, moved for dismissal or summary judgment, citing administrative law principles and discretion vested in the patent office.
What are the main findings?
- The Court upheld the USPTO’s rejection of GERON's patent claims.
- The Court found the patent office applied the proper legal standards, particularly relating to obviousness and patent-eligibility.
- The case clarified the extent of judicial review over USPTO patent decisions, affirming limited review for reasonableness but not for substituting judicial judgment for the PTO’s expertise.
What implications does this case have?
- Affirms deference to USPTO expertise in patent validity determinations.
- Reinforces the standards for patentability, particularly concerning obviousness.
- Limits the scope of judicial interference in patent prosecution decisions, emphasizing administrative discretion.
What are the key takeaways?
- Patent office procedures are protected from strict judicial review as long as they follow established law.
- Patent disputes involving biotech inventions face high scrutiny regarding obviousness.
- Litigation against USPTO decisions is unlikely to succeed if the agency provides a reasoned explanation consistent with patent law.
FAQs
Q1: Does this case set a precedent for future patent validity disputes?
Yes. It emphasizes that courts defer to USPTO determinations if they are based on reasonable interpretations of patent law, especially regarding obviousness.
Q2: Was GERON successful in claiming that the patent rejection was improper?
No, the court upheld the USPTO’s rejection, indicating procedural and substantive correctness.
Q3: How does this case impact biotech patent applications?
It underscores the importance of clear evidence addressing obviousness and patentability standards, as the USPTO rigorously applies these criteria.
Q4: Can a patent holder challenge USPTO decisions in court easily?
No. Courts show limited willingness to overturn administrative patent decisions unless there is clear procedural error or legal misconduct.
Q5: What role does Kappos play in this case?
As USPTO Director, Kappos’s role is administrative and represents the agency defending its patent rejections, emphasizing the agency’s legal expertise.
References
- Court docket and opinion summary, GERON CORPORATION v. KAPPOS, 1:09-cv-01553, District of Columbia.
